European Journal of Biomedical and Pharmaceutical Sciences

EFFECT OF ROSUVASTATIN ON DYSLIPIDEMIA IN HEMODIALYSIS PATIENTS

Ashwini A. Balode and Z. H. Khan*

ABSTRACT

Lipid disorders are one of the known metabolic changes associated with chronic renal failure (CRF).The prominent features of uremic dyslipidemia are an increase in plasma triglycerides and cholesterol in nearly all lipoproteins, and a reduction in high-density lipoprotein (HDL) cholesterol. Cardiovascular disease (CVD) is a major cause of mortality in patients with chronic renal failure (CRF). One of the risk factors for cardiovascular disease is dyslipidemia as it accelerates atherosclerosis. Therefore it is essential to study uremic dyslipidemia, since optimal treatment is essential for the prevention or delay of cardiovascular complications in patients on hemodialysis. Statins bind to and inhibit the enzyme 3-hydroxy-3- methyl-glutaryl coenzyme A Reductase, the rate limiting step in cholesterol biosynthesis. The inhibition of HMG-CoA reductase activity results in a drop in intracellular cholesterol production, thus improving the lipoprotein pattern. This study aims to evaluate the effect of Rosuvastatin on lipid parameters in hemodialysis patients in Akola district. A total of 200 hemodialysis patients were included: 150 were Rosuvastatin group and 50 were controls. As efficacy variables, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and triglyceride levels were determined at the start of the study and at post treatment. The parameters were estimated using commercially available kits on semiautoanalyser. The results showed that in the Rosuvastatin group there was a significant decrease from baseline to the study end in the mean total cholesterol (228.76± 19.80 mg/dL to 144.26± 17.81 mg/dL), in triglyceride level (172.09 28.44 mg/dL to 91.12 19.28 mg/dL) and in LDL- cholesterol from (152.20± 22.27 mg/dL to 76.17±18.38mg/dL). There was an effective increase in HDLcholesterol from 42.14± 5.80 mg/dL to 49.86± 3.43mg/dL. In the control group no significant decrease was observed. Rosuvastatin at 10 mg/day was associated with significant improvement in lipid profile in patients on regular hemodialysis.

Keywords: Rosuvastatin, Dyslipidemia, Cardiovascular disease, Hemodialysis.